Skip to main content

Professor Lyu Aiping named highly cited researcher 2023 by Clarivate Analytics


banner visual


Professor Lyu Aiping, Vice-President (Research and Development) of HKBU and Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine, is named “Highly Cited Researcher” for his publications ranked among Clarivate’s top 1% most cited publications for the category “cross-field” in Web of Science™. This annual list identifies the world’s most influential researchers whose peers have most frequently cited over the last decade. This year, 6,849 researchers from some 67 countries and regions across a diverse range of research fields have earned this extraordinary accolade. 


With his research interests and expertise in Chinese medicine and systems medicine, Professor Lyu has over 600 publications and obtained more than 60 patents from his research activities. He has achieved high Google Scholar citation counts of over 25,000, with a recent Google Scholar H-index score of 77. He is a leading figure in the standardisation of Chinese medicine diagnosis, and his distinguished accomplishments have been widely recognised by the numerous awards and prizes he has received.

Professor Lyu is a world-renowned scientist in aptamer-based translational medicine and drug discovery.  He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with the pharmaceutical industry for the development of novel therapeutic agents. He is the Director of the first aptamer research and development platform in the Guangdong-Hong Kong-Macao Greater Bay Area of mainland China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" at the Hong Kong Science Park. He has developed the world’s first-ever osteoblast-targeting nucleic acid aptamer. His first discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by the United States Food and Drug Administration (US FDA) (DRU-2019-6966) for evaluating the therapeutic potential for promoting bone formation in osteogenesis imperfect. 

Professor Lyu initiated a systems biology approach to identify metabolite biomarkers for subtyping rheumatoid arthritis (RA) patients with distinct clinical manifestations. His clinical research has underpinned the potent efficacy of Tripterygium wilfordii Hook F. based therapy for RA treatment, which is recommended by the Chinese Association of Integrative Medicine as the Evidence-based Clinical Practice Guidelines. 

The Highly Cited Researchers’ names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index, identifying the researchers’ institutions and countries where they are based. The methodology draws on data from the Web of Science™ citation index, in addition to analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information (ISI)™ at Clarivate.

Please click here for the full Clarivate Highly Cited Researchers 2023 List.

Our heartfelt congratulations to our prestigious researcher!